Catheter Precision shares surge 41.61% premarket after announcing $11.55M acquisition of Flyte/Ponderosa and $1.85M capital raise via preferred stock.

Catheter Precision surged 41.61% in premarket trading following the announcement of a $11.55 million acquisition of 80.02% in Flyte and 100% in Ponderosa from Creatd, alongside a multi-tranche private placement of Series C preferred stock with an initial $1.85 million raised and up to $35.56 million in additional funding potential. The moves, aimed at restructuring legacy operations, expanding the operating platform, and securing liquidity, were accompanied by resale registration rights for investors and Creatd, as well as a 0% promissory note to defer part of the acquisition cost. The strategic acquisitions and capital-raising efforts, supported by Dawson James Securities as placement agent, signaled renewed growth momentum and operational simplification, driving the sharp premarket rally.